Alumis (NASDAQ:ALMS) Given Overweight Rating at Cantor Fitzgerald

Alumis (NASDAQ:ALMS)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a report issued on Thursday,Benzinga reports.

Other research analysts have also issued reports about the stock. Guggenheim started coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 price objective for the company. Robert W. Baird began coverage on Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price objective on the stock. HC Wainwright reduced their price objective on Alumis from $30.00 to $26.00 and set a “buy” rating for the company in a report on Thursday. Leerink Partners initiated coverage on Alumis in a research note on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 price target for the company. Finally, Leerink Partnrs upgraded Alumis to a “strong-buy” rating in a research report on Tuesday, July 23rd. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $26.83.

Alumis Stock Down 4.8 %

ALMS opened at $10.81 on Thursday. The firm has a fifty day moving average price of $11.36. Alumis has a 1 year low of $9.54 and a 1 year high of $13.53.

Alumis (NASDAQ:ALMS) last released its earnings results on Tuesday, August 13th. The company reported ($23.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($21.53). On average, research analysts expect that Alumis will post -8 EPS for the current fiscal year.

Institutional Investors Weigh In On Alumis

A number of large investors have recently modified their holdings of ALMS. Towerview LLC acquired a new position in Alumis during the second quarter worth approximately $4,123,000. SR One Capital Management LP acquired a new stake in Alumis in the second quarter valued at $26,067,000. Ally Bridge Group NY LLC acquired a new position in Alumis during the second quarter worth about $8,229,000. Yu Fan acquired a new stake in Alumis during the 2nd quarter valued at $10,502,000. Finally, Millennium Management LLC purchased a new stake in Alumis during the 2nd quarter worth about $3,376,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.